The cluster has welcomed Karine Dalens on a fixed-term contract as a university technical assistant. After a baccalauréat in laboratory science and technology, Karine obtained an ANABIOTEC Higher Technician’s Certificate in 2018. This is her first post and she will be providing support in the Antibody Platform. We are delighted that she is joining us.
The Technology Cluster now benefits from a Biosafety L3 laboratory which contains three cubicles that are fully equipped for the production of viral vectors. Two are accessible to research teams from the Toulouse Cancer Research Centre, for the production of lentiviral vectors. The third cubicle is dedicated to the production of adenoviral and AAV vectors, the latter being produced on demand by the Platform’s staff. This L3 laboratory is managed by the Vectorology Platform, which also provides training for new users in the working procedures specific to this type of facility, and in the production of lentiviral vectors. For more information, you can contact Loïc VAN DEN BERGHE at: firstname.lastname@example.org
The Technology Cluster will be present for the first TOW, through two posters and two presentations.
Frédéric Lopez will be speaking during the “General Public” session on Thursday 4 February, at 18:00, about technologies and research in cancer.
On Friday 5 February, at 17:00, Laure Tonini will be telling the audience about the new technology developed by the Cluster, SWATH mass spectrometry, and the identification of biomarkers in the context of colorectal cancer (Friday 5 February at 17:00).
«Using 2D-DIGE for Proteomic Discovery of CDA-related pathways in Pancreatic Cancer», Nathalie Saint-Laurent, Frédéric Pont, Marion Gayral, Pierre Cordelier et Frédéric Lopez.
Marlène Dufresne (from the team led by Pierre Cordelier, CRCT), working in close collaboration with the Proteomics Platform of the CRCT Technology Cluster, has just published an article on protein biomarkers for the pre-neoplastic stages of pancreatic cancer. For the first time, this preclinical study using several mouse models that mimic the human disease has revealed the identity of plasma proteins that discriminate the different pre-neoplastic stages of PanIN (Pancreatic Intraepithelial Neoplasia) before the appearance of tumours. This study presages opportunities for the development of non-invasive approaches for the prediction and early detection of pancreatic adenocarcinoma.
You can see the article and its PubMed link on the Bibliography page.
Definitely a good read.
For several years now, the Technology Cluster has been developing an original strategy for the identification of interaction partners. This approach associates BIA (Biomolecular Interaction Analysis) technology to measure molecular interactions and SPR (Surface Plasmon Resonance) with Mass Spectrometry. The principle consists in immobilising the molecule of interest (DNA, RNA, protein, etc.) on a special surface (Sensorchip), injecting real-time a complex mixture, measuring the specificity of the interaction and recovering the partner(s) that have been fixed. As a second stage, the proteins thus recovered are identified using mass spectrometry.
This coupling of BIA and MS was exploited to identify the partners of P36, a peptide fragment derived from ALK (Cf. Aubry et al., Cell Death and Disease, on the Bibliography page), and to identify ITAFs, proteins that regulate the activity of IRES in FGF-1 (Cf. Ainaoui et al., Plos One on the Bibliography page).